Prime Insights

America’s opioid epidemic: Part 5 — the future of safer opioid use=

America’s opioid epidemic: Part 5 — the future of safer opioid use

The opioid crisis is staggering, but steps are being taken in the right direction. What will tomorrow hold for safer opioid use?

Important work being done on the opioid front

Section divider

    Recent insights

July 12, 2016 | Cathy Starner, PharmD, BCPS

America’s opioid epidemic: Part 4 — fighting overuse through legislation, advocacy and political action

Solving the opioid crisis goes beyond the private sector. To drive meaningful change, health care, government and industry groups all have to work together.  

Evidence-based policies that could help combat the crisis

July 8, 2016 | Cathy Starner

America’s opioid epidemic: Part 3 — strategies for curbing abuse

Combating the opioid crisis requires a full set of tools — and proof that they work. See how the research stacks up. 

Strategies to keep members safe and control the total cost of care

July 5, 2016 | Cathy Starner

America’s opioid epidemic: Part 2 — adding it up

To address the problem, we first have to gauge it. Prime’s researchers have worked to pinpoint who’s at highest risk for harm from controlled substances, such as opioids, and how this use potentially impacts the total cost of care. 

How can plan sponsors find high-risk users, and how does use impact the cost of care?

June 28, 2016 | Cathy Starner

America’s opioid epidemic: Part 1 — diagnosing the problem

Opioid drugs are killing more Americans than ever. Every health care stakeholder must take action. Prime explores the ins and outs of opioid overuse and management in our latest five-part series.

Who's using opioids, and who can help curb this deadly trend?

April 29, 2016 | Kevin Bowen

4.5-year study finds diabetes and related drug costs surging

By 2050, as many as 1 in 3 adults in the United States will have diabetes. Coupled with drug price inflation, rising diabetic drug use has led to mounting costs for plan sponsors. To help measure the impact of rising use and costs, our team dove deep into Prime’s data to study diabetes prevalence, incidence and drug therapy.

What we learned | Study poster

April 28, 2016 | Kevin Bowen

What can drug therapy tell us about severe hypoglycemic events?

Hypoglycemia can trigger serious symptoms, such as impaired vision, seizures and unconsciousness.
To better understand if and how emergency department visits for hypoglycemia are related to diabetes types and drug regimens, our team studied data from nearly 4 million members. 

What we learned | Study poster

April 26, 2016 | Cathy Starner

Can alerts at the pharmacy counter help curb opioid use?

Opioid misuse has emerged as an epidemic. The Centers for Medicare and Medicaid Services has implemented an opioid overutilization monitoring system. But is it enough? My team and I recently explored whether additional opportunity to curb opioid use existed. 

What we learned | Study poster

April 22, 2016 | Cathy Starner

Taken together, triple threat drugs prove dangerous — and costly

As administrators of prescription drug programs, pharmacy benefit managers can play an important role in helping prevent opioid overdose deaths. Prime reviewed data from 15 million members to study the impact of “Triple Threat” drug use.

What we learned | Study poster

Section divider